Evidence map›Paper›PMID 32921826›Full record

ArticleReumatologia2020

Blood calprotectin in children with juvenile idiopathic arthritis: relationship to flare development after discontinuation of treatment.

Yaryna Boyko, Viktoriia Ivanova, Maryna Vakaruk, Tamila Kozina, Nataliia Shevchenko, Nataliia Vaizer, Olha Synoverska, Oksana Chubata, Olha Marchuk, Anna Havrylyuk

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Reumatologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Yaryna BoykoDepartment of Pediatrics, Western-Ukrainian Specialized Children's Medical Centre, Lviv, Ukraine.
Viktoriia IvanovaCommunal Non-profit Enterprise Regional Clinical Children's Hospital of Kirovohrad Regional Council, Kropyvnytskyi, Dnipropetrovsk National Medical University, Kropyvnytskyi, Ukraine.
Maryna VakarukRegional Children's Clinical Hospital, Odessa, Ukraine.
Tamila Kozina"Medykgrup", Kherson, Ukraine.
Nataliia ShevchenkoInstitute of Healthcare of Children and Adolescents of the National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine.
Nataliia VaizerMariupol Territorial Medical Association of Woman's and Child's Health, Ukraine.
Olha SynoverskaIvano-Frankivsk National Medical University, Ukraine.
Oksana ChubataTernopil Regional Children's Hospital, Ukraine.
Olha MarchukVinnytsia Regional Children's Clinical Hospital, Ukraine.
Anna HavrylyukDepartment of Clinical Immunology and Allergology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
Kyiv City Clinical Oncology Center · UACentral Ukrainian National Technical University · UADanylo Halytsky Lviv National Medical University · UAIvano-Frankivsk National Medical University · UAKherson State University · UALviv City Children's Hospital · UAState Institution "Institute for Children and Adolescents Health Care at the National Academy of Medical Sciences of Ukraine" · UAWest Ukrainian National University · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe study aim was to prospectively evaluate the relationship between disease flare development in children with juvenile idiopathic arthritis (JIA) after discontinuation of treatment and serum calprotectin levels (MRP8/14). MATERIAL AND

methodsDetermination of blood serum level of calprotectin was performed in 54 patients with inactive JIA from various regions of Ukraine. The inclusion criterion was the existence of an inactive state of the disease in children with JIA for at least 6 months. During 1 week after blood sampling for determination of serum calprotectin (MRP8/14) level the patients were completely discontinued of all therapy. Determination of calprotectin level in blood serum was performed with reagents EK-MRP8/14 Buhlmann (MRP8/14; S100A8/9), Switzerland, using the ELISA method.

resultsThe trial results showed that 3 months after discontinuation of treatment in patients with inactive JIA, the flares developed in 5 out of 54 patients (9.3%). The median calprotectin level before discontinuation of the treatment was 1,700 ng/ml in patients who developed a flare, and 1,500 ng/ml in other studied patients (not statistically significant). At 6 months, the flare had developed in an additional 3 out of 48 (6.3%) of patients, who continued to be followed up, while their median calprotectin serum levels were 1,300 ng/ml and 1,500 ng/ml respectively (not statistically significant). At 12 months, the flares had developed in 13 more out of 45 (28.9%) patients, who continued to be followed up, while the median calprotectin serum level in these patients before discontinuation of treatment was 1,100 ng/ml and 1,650 ng/ml respectively (not statistically significant).

conclusionAfter discontinuation of treatment a flare over the next year of follow-up developed in 38.9% of patients. The study results did not reveal a significant difference in calprotectin level in patients with JIA prior to complete discontinuation of treatment who developed a flare and those without a flare after 3, 6 and 12 months.

Indexed as

biomarkersblood calprotectinflarejuvenile idiopathic arthritis

Identifiers

PMID32921826
PMCPMC7477479
OpenAlexW3082102065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.